trial. These studies will be aimed at determining if IL-3 can stimulate stem cell proliferation. Dr. Gabrilove, your comments? DR. GABRILOVE: Besides the four classic colonystimulating factors Dr. Moore mentioned, there are a host of other hematopoietic growth factors, which are being shown also to have colony-stimulating activity. I'd like to point out some of their differences in terms of the stage at which they work. IL-3 appears to act on very immature progenitor cells in vitro. It causes them to proliferate and enhances cell maturation. As Dr. Moore has mentioned, it can act on mature end cells as well.
DR. McGUIRE:
Two nonclassic colony-stimulating factors, interleukin-1 (IL-1) and interleukin-6 (IL-6), also appear to be as important and may turn out to be even more important than IL-3 in promoting the survival, proliferation, and cycle activation of resting stem cells. Animal studies have shown that the effect of IL-3 on stem cell proliferation is not as great as would have been expected from in vitro data. Therefore, there are other early acting stem cell factors that are not part of the classic colonystimulating-factor family, but that may become more important in the future.
GMCSF acts at the next stage of cell development. In vitro studies have shown that it acts on more committed progenitors. These cells, however, still have the capacity to give rise to erythroid and myeloid elements. In addition, this particular substance can support the growth of committed progenitor cells for the myeloid series. One way in which GMCSF differs from GCSF is that GM appears to act on a broader range of granulocytes. It seems to support the growth of eosinophil granulocytes, as well as neutrophils, and, some believe, basophil granulocytes. On the other hand, GCSF, which should probably be called neutrophil colonystimulating factor, appears to be very neutrophil granulocyte specific.
The classic lineage-specific factors are MCSF, which Dr. Moore mentioned, and GCSF, which support monocyte/macrophage and neutrophil granulocytes, respectively. One other point: There are several ways in which GMCSF and GCSF differ biologically in their action in the body. GMCSF has been shown in vitro and in humans to inhibit neutrophil granulocyte migration, whereas GCSF does not. One way to look at this is that when injury occurs, GMCSF may be produced locally at the site of inflammation, since it is not normally found in the serum. This inhibits the migration of inflammatory cells away from the injury site. GCSF, on the other hand, would enhance the migration of the cells towards the site of inflammation. This may be one way in which the two substances work in concert under normal physiologic conditions. DR. GABRILOVE: This is a very large and rapidly expanding area of investigation. So far, I think there are three major areas in which colony-stimulating factors, primarily GCSF and GMCSF, have been evaluated. First, these factors have been studied in patients without hematopoietic diseases prior to their receiving chemotherapy, in an effort to understand these factors' normal biology, and, in the case of GMCSF, its ability to act as a primary anticancer agent by stimulating effector cell function.
Second, initially GCSF and, more recently, GMCSF have been studied for their ability to either protect completely or accelerate recovery from myelosuppressive therapy, such as chemotherapy alone or chemotherapy and/or radiation therapy in the setting of bone marrow transplantation.
The last area has been the use of these factors in treating neutropenia in patients with hematopoietic diseases, such as those with myelodysplastic syndrome and hairy cell leukemia, and in patients with primary nonmalignant neutropenic diseases, such as congenital neutropenic Kostman's syndrome, idiopathic neutropenia, and cyclic neutropenia. DR. RINEHART: The major results from our studies using GCSF or GMCSF have been a shortening of the neutropenic period in patients given these factors after receiving chemotherapy. There have been no significant effects seen yet, however, on the period of chemotherapy-associated thrombocytopenia.
DR. GABRILOVE: Certainly based on our studies, as well as those of Morstyn in Australia and Scarfe in England, several statements concerning the usefulness of these factors can be made.
In our study with GCSF, we were able to show that the number of days that patients experienced neutrophil counts of less than 1000 was significantly fewer when they were given GCSF. The British group found the same when they gave patients GCSF during alternating cycles of chemotherapy over a 6-month period. We treated patients with bladder cancer; the British treated patients with small cell lung cancer. The Australian group had the same findings in patients with a variety of solid tumors who were being treated with high-dose melphalan.
These studies certainly suggest that the patients who experienced fewer days of neutropenia also had a decreased need for antibiotics to treat febrile neutropenia, which, of course, is a significant cause of morbidity and, sometimes, mortality in cancer patients. These findings did not reach statistical significance because these were early studies not designed to answer this particular question.
We had two other findings of interest. Patients who received GCSF were able to receive full doses of chemotherapy on schedule. Whether this will translate into an improved antitumor response remains to be determined. We also observed that another toxicity of chemotherapy, mucositis, ap-peared to decrease in patients given GCSF. We think that's quite interesting, because neutrophil granulocytes are normally lost through the gastrointestinal mucosa. GCSF may have some property to enhance the kinetics of neutrophil loss that may be contributing to mucosal healing. As far as GMCSF, the study by Dr. Karen Antman suggested that it caused a decrease in the number of days of neutropenia following chemotherapy. Dr. Bill Peters's elegant study of GMCSF in bone marrow transplant recipients also demonstrated a decrease in the time to recovery of neutrophil counts and suggested a decrease in the incidence of bacteremia. Although the data is certainly preliminary in all these studies, it's certainly very exciting and deserves substantial further investigation. DR. MOORE: Well, as Dr. Gabrilove has pointed out, the effects of colony-stimulating factors on neutrophil reconstitution and their efficacy in all these situations, be it radiation, bone marrow transplantation, chemotherapy, or idiopathic and congenital neutropenia, are very clear cut.
Dr. Rinehart raised an important question. Although we've generated more than a dozen growth factors that affect differentiation of early hematopoietic cells and, in some cases, more mature neutrophils and macrophages and so forth, we have not been particularly effective in generating growth factors that can affect platelet recovery. Preclinical evaluation in primate model systems has given some hope that IL-1 might be an effective agent in accelerating platelet recovery. In those studies, primates were exposed to, for example, 5-fluorouracil or autologous bone marrow transplantation. IL-1 not only accelerated neutrophil recovery but also, in contrast to GMCSF, apparently accelerated platelet recovery. Therefore, there is a research area that suggests the possibility that a cytokine has an advantage in stimulating lineages other than the granulocyte pathway.
When we discuss the efficacy of hematopoietic growth factors, we must appreciate the need to synchronize or integrate them with whatever chemotherapy is being administered. Since nature has provided these factors in a multiplicity of forms with overlapping and pleiotropic effects, we should be cognizant of the need to combine them in ways that we have not yet begun to fully realize. I think there are several areas in which these agents might be used. Several of them have been mentioned. First, they are promising in reversing the cytopenia associated with what we now call standard chemotherapy. The second major area is the allowance of dose intensification. There have been a number of studies in which very large doses of chemotherapy, near bone marrow transplantation doses, have been given. GCSF, GMCSF, and IL-3 may allow that kind of therapy to become more widespread. The third area is, obviously, that of autologous or allogeneic bone marrow transplantation, in which these factors are given to hasten the recovery and proliferation of the transplanted bone marrow. Fourth, as already alluded to, these agents may help correct hypoplastic and dysplastic states. But a word of caution here. Both laboratory and clinical work, particularly Dr. Moore's investigations, have shown that these agents support proliferation of not only normal stem cells but leukemic stem cells as well. So, it's not certain that these agents will be useful in every patient with dysplastic diseases. Fifth, there are some interesting data, which will probably lead to a trial by the Southwest Oncology Group, showing that GMCSF can be used to cycle leukemic cells before administration of chemotherapy. A major problem in treating leukemia, of course, is that a significant fraction of leukemic blasts have relatively infrequent proliferation cycles, which is virtually the only time when current chemotherapeutic agents are active. Unfortunately, we only have phase I trials from which we can currently obtain data, although there are some phase III trials already under way. DR. GABRILOVE: To add to Dr. Rinehart's eloquent statements: I think there are two other interesting potential uses of these factors. One comes from the observation that both GCSF and GMCSF increase the number of hematopoietic progenitors in patients receiving these factors. The potential is to use these agents to prime donation of blood for autologous transplantation to increase the number of progenitors in that blood sample so as to possibly complement or even obviate the need for harvesting bone marrow. There is quite a bit of enthusiasm for pursuing this approach in the future.
Also, as Dr. Moore mentioned in the very beginning, all of these factors enhance various effector cells which, in turn, have the capacity to kill tumor cells both directly and, particularly in combination with monoclonal antibodies, through a mechanism referred to as 'antibody-dependent cytotoxicity.' I think the use of these hematopoietic growth factors to increase the number, efficiency, and functional action of these effector cells in combination with monoclonal antibodies will be pursued clinically, as it has been by several investigators working with in vitro and in vivo animal models. DR. MOORE: The word specific is very important here. I think we have to recognize that each malignancy, certainly in the case of leukemias and lymphomas, is a unique clonal event. As such, while we can generalize about the overall treatment of patients, it seems to me that we have the technological tools to preevaluate individual patients. For example, looking at the bone marrow response of chemotherapy or transplant patients to various growth factors in terms of maturation, or induction of proliferation or synchronization, is it possible to intensify chemotherapy with adjuvant growth factor therapy?
One of my thoughts as a basic scientist in this discussion is to suggest that we pay more attention to the need to understand the individual's particular clonal malignancy, addressing questions such as whether the patient's tumor cells have receptors for the different growth factors; whether they are likely to respond by proliferation or differentiation; and whether we can synchronize the leukemic blast cells. I think the answers to these questions are all within the range of current technology, at least in most major cancer centers. DR. GABRILOVE: Data from animal studies are accumulating to suggest that the use of hematopoietic growth factors can be useful in managing nonmalignant conditions. I'm more familiar with the data from animal studies in which GCSF was used to protect against overwhelming bacterial infections. While further investigations are needed, there appears to be a role for these growth factors in augmenting effector cell function, in this particular situation neutrophil granulocytes. Other growth factors may augment a wider range of effect on cell
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function in terms of fighting several types of infectious diseases when given alone or in combination with antibiotic therapy. We could envision these factors being used in the setting of individuals at risk for infections, for example, an elderly patient undergoing prostatic surgery, in which there is a high incidence of gram-negative infections postoperatively.
There is quite a bit of interest in using colonystimulating factors in patients with burns to augment neutrophil granulocyte, monocyte, and macrophage function. The concern here is that we know too little about normal physiologic levels of these factors and their levels in a variety of disease states to make a judgment about whether administering additional amounts of colony-stimulating factors will make a difference in infectious episodes. Much more work needs to be done in animal models and in vitro to know what the normal factor levels are before we pursue their more aggressive use in burn patients.
DR. McGUIRE: Thank you, Dr. Gabrilove. Dr. Rinehart, your thoughts on the use of these factors in nonmalignant diseases?
DR. RINEHART" Another area I'd mention is the use of these agents in patients with HIV infections. As Dr. Gabrilove has mentioned, these factors may have a possible usefulness in stimulating neutrophil cell function in patients to increase their resistance to intracellular macrophage parasites.
The other possible use is in patients, particularly elderly patients, who have undergone long-term care and develop what amounts to bone marrow exhaustion. This subset of patients who have had numerous infections have hyperplastic bone marrows. IL-3 or some other agents may be useful in these patients to stimulate stem cell proliferation and expansion. DR. MOORE: We have been studying neonates and have measured colony-stimulating factors in cord blood. It is clear that neonates have a dramatic elevation of GCSF and GMCSF levels at birth. The possibility exists that neonatal septicemia, one of the major causes of infant mortality, is a reflection of some abnormality in either the production of or response to colony-stimulating factors.
I would like to address the issue of the use of these agents in autologous or allogeneic transplantation, not necessarily in the context of cancer, though obviously that is always one of the potential uses of this procedure. Purging procedures that remove graft-versus-host reactive T cells and, also, possibly contaminating tumor cells do not always lead to effective engraftment. One of the issues, therefore, is whether we are removing critical accessory cells in the bone marrow, which are producing growth factors necessary for stem cells to replicate in their new environment.
It has become clear in preclinical trials in primate and murine models that administering growth factors, such as IL-1, IL-3, GCSF, and GMCSF, alone or in combination, is very effective in enhancing both the survival and the amplification and differentiation of transplantable stem cell populations. I think this is an important area where growth factor therapy should be utilized.
DR. RINEHART: One other area we have not mentioned is other transplantations. There is a rapidly increasing population of heart, renal, and liver transplant patients who are all immunosuppressed and in whom these agents might be helpful. DR. GABRILOVE: I would like to address one area to which I alluded earlier -that is, the treatment of primary neutropenia disorders and also secondary neutropenia, such as drug-induced agranulocytosis. Both conditions may respond to treatment with hematopoietic colony-stimulating factors. Again, the greatest experience has been with GCSF in treating idiopathic neutropenia, cyclic neutropenia, and Kostman's syndrome. Interestingly, it has been observed that when the bone marrow from some of these patients is grown in the presence of GCSF it will give rise to neutrophil colonies, whereas in the presence of GMCSF one only sees eosinophil and monocyte/macrophage colonies. This suggests that there may be some defect in the GCSF pathway, either in the expression of the gene or its protein, or at the receptor level. Various data, then, are accumulating to show that GCSF is quite effective in restoring normal neutrophit counts and reducing the number of infectious episodes. Also, it has been shown to promote the complete healing of oral ulcerations. DR. MOORE: I'd like to make a brief comment concerning two other hematopoietic defects. The first is cyclic neutropenia, in which there is a defect in the regulation of colony-stimulating-factor production. Certain genetic model systems have shown that it is clearly treatable by administering GCSF, but does not appear to respond to GMCSF. The second is aplastic anemia, which we have not yet discussed. Here, GMCSF appears, at least in preliminary clinical studies, to help recovery of hematopoietic function. DR. GABRILOVE: The acute side effects reported from colony-stimulating factors have been from use of GCSF and GMCSF. In the case of GCSF, the major side effect has been generally mild bone pain, which occurs almost exclusively with the short-infusion route of administration and appears to be associated with the peak serum concentration levels achieved. In the case of GMCSF, a number of routes of administration have been used and side effects have been observed. The major side effects have been phlebitis when administered intravenously via peripheral sites. There have also been some reports of thrombosis formation when this factor is administered at higher doses even through central vein catheters.
Regardless of the route or duration of infusion, most studies involving GMCSF have reported some degree of fever and myalgia.
When GMCSF is given via a short half-hour infusion, gastrointestinal irritation and nausea have been reported. I believe that this was a doselimiting toxicity in a study reported from Arizona. At high doses, GMCSF has been associated with higher fevers, serositis, and respiratory problems consisting of pulmonary edema, pulmonary emboli, and pleural effusion.
More recently, Dr. Peters has suggested that the side effects seen with higher doses of GMCSF appear to be correlated with increased serum levels of tumor necrosis factor. As mentioned before, I think it is important that we remember the network effect of hematopoietic factors when we administer a specific colony-stimulating factor. Since GMCSF is a potent activator of monocytes and macrophages, some of the cytokines it induces may play a role in causing the side effects observed. It is interesting to note, of course, that GCSF is not a potent activator of monocytes and macrophages, which may be one of the reasons we do not see this same profile of side effects.
In terms of anticipated side effects, I think the major concern is whether prolonged stimulation by any growth factor might have consequences. Most of us feel that, at least in the setting of cancer treatment, these factors will be used for very limited periods. What we would really be doing is mimicking what the body does normally by providing these factors a bit sooner.
The final area of concern is depletion of stem cells with agents that place a constant demand on the hemopoietic system. So far, there has been no evidence for that in animal models, but investigators are concerned about it. I'm sure that Dr. Moore can speak more directly to this point.
DR. McGUIRE: Dr. Rinehart, your view of the question of toxicity?
DR. RINEHART: One anticipated side effect is the induction of normal stem cell cycling in close approximation to the time at which chemotherapy is administered. In other words, administering these factors before or very soon after chemotherapy might actually induce cycling of stem cells and lead to enhanced chemotherapy damage to stem cells. Again, this has not yet been a reported problem.
A second problem, of course, has already been alluded to -that is, the possibility that if one treats patients who have stem cell disorders, such as myelodysplastic syndrome, one might induce proliferation of the malignant stem cells. DR. McGUIRE: Dr. Moore, your opinion about side effects?
DR. MOORE: As Dr. Gabrilove discussed, we are studying the issue of stem cell effects, particularly the exhaustion of stem cells in animal models. We have subjected animals to repeated courses of highdose chemotherapy, together with prolonged administration of GCSF or other growth factors, such as IL-1 or GMCSF. Depending on whether one is giving an alkylating agent or an antimetabolite, in general there is no evidence that one exhausts the hematopoietic stem cells' capacity to self-renew and differentiate. In preclinical experimentation, we also have no evidence that this prolonged growth factor therapy is leukemogenic. Indeed, GCSF would appear to be effective in suppressing the emergence of myeloid leukemic clones in various transplantable leukemic models.
There is another feature we should consider when discussing how to integrate the use of hematopoietic growth factors with chemotherapy or radiation therapy, and that is the issue of the proliferative status of the stem cell, which is very critical. We cannot make an a priori assumption based on the pharmacokinetics of either the drugs or the growth factors we are using to determine an appropriate course or time of administration. Certainly, administering growth factors simultaneously with chemotherapy is not the best approach. The question is whether we should wait 24 hours, or 3 days, or even longer after chemotherapy to administer GCSF or another agent. I think these issues must be resolved in very controlled clinical trials. My feeling now is that we are faced with a burgeoning number of these growth factors; as I said at the outset of these discussions, nearly a dozen of these factors are now being cloned. We have developed an understanding of their biologic efficacy in preclinical models. We have clinical information about four of them. All of these developments have occurred within 2 or 3 years. The question we are asking here is how best to integrate these new agents with the conventional triad of surgery, radiation therapy, and chemotherapy, and also, I suppose, antibiotic treatment. I suspect that we are going to look back on the data about GCSF, GMCSF, or the other factors from the late 1980s and say that the idea of a single-agent treatment, or single-agent chemotherapy, was extraordinarily naive.
In the 1990s, we will probably be talking about multiple growth factor administration. The logic of this is based on our knowledge that the early hematopoietic stem cells, which give rise to the immune as well as the blood-forming cells, respond to positive and negative signals provided by agents such as IL-1, IL-6, tumor necrosis factor, interferon gamma, transforming growth factor beta, and the like. These stem cells give rise to a series of progenitors that respond to other interleukins and other colony-stimulating factors required continuously throughout the process of proliferation and differentiation.
Our task is to find out why these different growth factors exist and what their best combinations are. Should they be given sequentially or additively in order to optimize whatever we are trying to protect or initiate, be it immune potentiation or hemopoietic system reconstitution? I see this as our future goal to be integrated with the current status of cancer chemotherapy. DR. RINEHART: I agree with Dr. Moore. I think that the combination of various factors with chemotherapy is going to result in multidrug and multibiologic therapy. However, it will be difficult to evaluate these enormous numbers of agents in patients. I think we need improved animal models that will allow us to be more predictive of their usefulness in humans.
DR. McGUIRE: Dr. Gabrilove, your comments? DR. GABRILOVE: I would agree that we need additional animal models, but would mention that the rhesus and cynomolgus monkey models have been quite helpful in complementing murine models for predicting the response and effects of these growth factors, especially in the setting of chemotherapy. What we need, also, is a decrease in the cost of these models.
DR. McGUIRE: Any final comments on today's discussion?
DR. MOORE: I believe that these biologic agents should be considered in a different light from chemotherapeutic agents. These are natural products whose biologic functions are well characterized, so we are not dealing with total unknowns. I think that we can move to combine these agents in the clinical setting without having to go through the 4 or more years that it has been taking. I think we could shorten that time interval considerably.
DR. RINEHART:
Of all the biologic agents that have come before clinicians over the last 10 years, these growth factors hold the most promise for broad usefulness in treating cancer and cancer-related disorders. I totally agree with Dr. Moore that all animal and human studies so far have suggested that these are very benign agents. We should move rapidly into clinical trials.
